Logo
Atomo Diagnostics Investor Hub

Why invest in Atomo

The case for AT1

Four reasons investors back us

01

Revenue that is growing, not promised

FY26 revenue reached A$5.3 million, up 41%, with both established channels contributing: HIV tests up 21% to A$2.8 million and partner supply up 209% to A$2.2 million. Our underlying EBITDA loss narrowed 39% over the same period, so growth is starting to show operating leverage rather than just scale.

02

A regulatory footprint that opens doors

We hold approvals with the TGA, WHO Prequalification, CE Mark across the UK and Europe, ANVISA in Brazil, Health Canada and the FDA. The FDA CLIA waiver secured on our Pascal platform matters most: a CLIA waiver typically expands the addressable market for a rapid blood test more than tenfold, and it gives our own tests a predicate pathway into the United States.

03

Technology we own outright

Seven patent families and more than forty registered patents across thirty plus countries protect the integrated device design that makes our tests simple enough to be used without supervision. In US clinical trials, Pascal delivered greater than 99% concordance between trained and untrained users. That is a defensible position, not a licence.

04

Several ways to win, on one platform

Active syphilis has completed development, liver function has entered the pipeline, and partner programmes with Chromacare and a UK customer are in validation. Every one of them runs on hardware we already manufacture, and grants and licensing have funded much of the development, so the downside of any single programme slipping is contained.

The market in front of us

HIV self testing alone is a A$200 million opportunity

Self testing is moving from novelty to standard of care. Pharmacy and retail now range consumer rapid tests, public health programmes are funding at home testing, and regulators are supportive. We are already registered and selling in the markets where that shift is happening fastest.

A$200m
HIV self test serviceable obtainable market, global excluding the US
10%
Annual growth rate of the self test market
10x
Typical uplift in addressable market once a rapid blood test holds a US CLIA waiver
6x
Our target growth in Australian pharmacy footprint over three years

Serviceable obtainable market estimated by Atomo based on 2025 data. On the partner side, Lumos Diagnostics has signed a six year agreement with PHASE Scientific for supply of FebriDx in the US and has stated it anticipates FebriDx product revenues of up to US$317 million over that term, assuming contracted minimum order quantities are achieved. Every FebriDx test sold requires Lumos to order a Pascal cassette from us, and we receive a portion of the proceeds based on the Pascal transfer price. Figures as at our FY26 results, released 31 August 2026.

The last twelve months

How FY26 unfolded, and what comes next

  1. January to March 2026

    Order flow and a fourth indication

    Two HIV orders into LMIC markets worth $500k and $410k, a $630k NAPWHA order in ANZ, an exclusive global licence for a liver function test, and two new Pascal customers signed.

  2. April 2026

    FDA CLIA waiver for FebriDx

    Lumos secured a CLIA waiver on our Pascal platform, unlocking US point of care volume and a predicate pathway for our own tests. We also completed a A$3 million capital raise.

  3. June 2026

    Syphilis development complete

    Active syphilis finished technical development with sensitivity above 85%, and technology transfer to manufacturing began. We closed the year with A$3.7 million cash and no debt.

  4. August 2026

    FY26 results and a new CEO

    Revenue up 41% to A$5.3 million with EBITDA improved 39%. Dr. Cheri Walker stepped up from the board as Interim CEO, moving our leadership closer to the US and Europe.

  5. September 2026

    Strategy set out to investors

    Dr. Walker took shareholders through the FY26 result and the plan for the next phase of growth, then answered questions live. The replay is on our webinars page.

  6. 3 November 2026

    Q1 FY27 quarterly webinar

    Our first read on FY27. Dr. Walker will take investors through the Q1 quarterly and answer questions live at 2:00pm AEDT. Registration is open now.

Come along for the ride

Hear it from us first

Register on this hub and we will send you our ASX announcements, quarterly results and webinar invitations as they happen. You can also ask our leadership team a question ahead of any webinar.